Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations.

Front Oncol · 2023 · PMC10315455 · PMID 37404764

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

showed a trendp = 0.059so close (0.05 < p ≤ 0.1)

Notably, even in the subgroup of those patients with “favourable” characteristics (those with ECOG 0, normal LDH, and no M1c disease), starting with nivolumab and ipilimumab showed a trend for improved OS (86.2 vs. 54.1 months p = 0.059).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.